CN114028589A - Composite lysozyme sterilization and disinfection type ultrasonic coupling agent and preparation method thereof - Google Patents
Composite lysozyme sterilization and disinfection type ultrasonic coupling agent and preparation method thereof Download PDFInfo
- Publication number
- CN114028589A CN114028589A CN202111481039.6A CN202111481039A CN114028589A CN 114028589 A CN114028589 A CN 114028589A CN 202111481039 A CN202111481039 A CN 202111481039A CN 114028589 A CN114028589 A CN 114028589A
- Authority
- CN
- China
- Prior art keywords
- parts
- lysozyme
- sterilization
- coupling agent
- type ultrasonic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000016943 Muramidase Human genes 0.000 title claims abstract description 38
- 108010014251 Muramidase Proteins 0.000 title claims abstract description 38
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title claims abstract description 38
- 239000004325 lysozyme Substances 0.000 title claims abstract description 38
- 229960000274 lysozyme Drugs 0.000 title claims abstract description 38
- 235000010335 lysozyme Nutrition 0.000 title claims abstract description 38
- 238000004659 sterilization and disinfection Methods 0.000 title claims abstract description 23
- 239000007822 coupling agent Substances 0.000 title claims abstract description 21
- 239000002131 composite material Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 14
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 14
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 14
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 12
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 claims abstract description 11
- 229940093424 polyaminopropyl biguanide Drugs 0.000 claims abstract description 11
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 10
- 239000000661 sodium alginate Substances 0.000 claims abstract description 10
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 10
- 239000008213 purified water Substances 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229940123208 Biguanide Drugs 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- -1 poly (aminopropyl biguanide Chemical compound 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 239000003899 bactericide agent Substances 0.000 abstract description 3
- 229960005150 glycerol Drugs 0.000 abstract 1
- 229940074410 trehalose Drugs 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 7
- 230000003385 bacteriostatic effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229960003500 triclosan Drugs 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Radiology & Medical Imaging (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a composite lysozyme sterilization and disinfection type ultrasonic coupling agent, which comprises lysozyme, polyaminopropyl biguanide, benzalkonium chloride, sodium alginate, trehalose, glycerol and purified water. The invention also discloses a preparation method of the composite lysozyme sterilization and disinfection type ultrasonic coupling agent. The invention relates to a composite lysozyme sterilization and disinfection type ultrasonic coupling agent, wherein lysozyme, polyaminopropyl biguanide and benzalkonium chloride are bactericides. Trehalose and glycerol are used as skin protectant.
Description
Technical Field
The invention relates to a sterilization and disinfection type ultrasonic coupling agent of composite lysozyme and a preparation method thereof, belonging to the technical field of medical ultrasonic imaging agents.
Background
The medical coupling agent is a medical product consisting of a new-generation aqueous polymer gel. The pH value of the ultrasonic probe is neutral, the ultrasonic probe is non-toxic and harmless to a human body, is not easy to dry and rancidity, has clear ultrasonic imaging, proper viscosity and no oiliness, the probe is easy to slide, can wet the skin, eliminates the air on the surface of the skin, and has good lubricating property and easy unfolding; has no corrosion and damage to the ultrasonic probe. The bactericide used in the sterilizing couplant on the market is mainly triclosan, the solubility of triclosan in water is poor, and oil and fat raw materials such as castor oil and the like are required to be added in the production process to improve the solubility of triclosan, so that the equipment is extremely difficult to clean after production. In addition, corresponding restrictions are currently made internationally in view of the risks associated with the use of triclosan.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide the composite lysozyme sterilization and disinfection type ultrasonic coupling agent and the preparation method thereof, and the formula of the coupling agent is optimized, so that the ultrasonic coupling agent can ensure the disinfection effect, is nontoxic and harmless to the human body and has clear ultrasonic phenomenon.
In order to achieve the purpose, the invention adopts the following technical scheme:
the composite lysozyme sterilization and disinfection type ultrasonic coupling agent comprises the following components in parts by weight:
0.1-0.5 part of lysozyme, 0.5-1 part of poly aminopropyl biguanide, 0.1-0.5 part of benzalkonium chloride, 1-6 parts of sodium alginate, 1-5 parts of trehalose, 2-5 parts of glycerol and 100 parts of water.
The invention also provides a lysozyme skin disinfectant with a skin protection function and a preparation method thereof, and the lysozyme skin disinfectant comprises the following steps:
s1 is prepared directly by taking 50-100 parts of purified water, adding 0.1-0.5 part of lysozyme, stirring for dissolving, adding 0.5-1 part of poly aminopropyl biguanide and 0.1-0.5 part of benzalkonium chloride, and preparing into solution A.
S2 adding trehalose 1-5 parts into 50-100 parts of water, dissolving, adding sodium alginate 1-6 parts, heating and stirring to gel state to obtain solution B.
And S3, adding the solution B into the solution A obtained in the step S1, stirring uniformly, and adding 2-5 parts of glycerol.
And S4, stirring and defoaming in vacuum to obtain the coupling agent.
The invention has the beneficial effects that:
the lysozyme can effectively hydrolyze peptidoglycan of bacterial cell walls, and can be used as a natural anti-infective substance with bactericidal effect. Has antibacterial, antiviral, hemostatic, repercussive, analgesic, and tissue recovery promoting effects.
The trehalose can form a special protective film on the surface layer of the skin, and mucus separated out from the film not only moistens skin cells, but also has the function of radiating external heat, thereby protecting the skin from being damaged.
Detailed Description
The present invention will be further described below, and it should be noted that the present embodiment is based on the technical solution, and a detailed implementation manner and a specific operation process are provided, but the protection scope of the present invention is not limited to the present embodiment.
Example 1
The embodiment provides a composite lysozyme sterilization and disinfection type ultrasonic coupling agent and a preparation method thereof, wherein the ultrasonic coupling agent comprises the following components in parts by weight:
0.1-0.5 part of lysozyme, 0.5-1 part of poly aminopropyl biguanide, 0.1-0.5 part of benzalkonium chloride, 1-6 parts of sodium alginate, 1-5 parts of trehalose, 2-5 parts of glycerol and 100 parts of water.
The invention relates to a composite lysozyme sterilization and disinfection type ultrasonic coupling agent, wherein lysozyme, polyaminopropyl biguanide and benzalkonium chloride are bactericides. Trehalose and glycerol are used as skin protectant. The lysozyme can effectively hydrolyze peptidoglycan of bacterial cell walls, and can be used as a natural anti-infective substance with bactericidal effect. Has antibacterial, antiviral, hemostatic, repercussive, analgesic, and tissue recovery promoting effects.
The trehalose can form a special protective film on the surface layer of the skin, and mucus separated out from the film not only moistens skin cells, but also has the function of radiating external heat, thereby protecting the skin from being damaged.
Example 2
The embodiment provides a preparation method of the composite lysozyme sterilization and disinfection type ultrasonic couplant as described in embodiment 1, which comprises the following steps:
s1 is prepared directly by taking 50-100 parts of purified water, adding 0.1-0.5 part of lysozyme, stirring for dissolving, adding 0.5-1 part of poly aminopropyl biguanide and 0.1-0.5 part of benzalkonium chloride, and preparing into solution A.
S2 adding trehalose 1-5 parts into 50-100 parts of water, dissolving, adding sodium alginate 1-6 parts, heating and stirring to gel state to obtain solution B.
And S3, adding the solution B into the solution A obtained in the step S1, stirring uniformly, and adding 2-5 parts of glycerol.
And S4, stirring and defoaming in vacuum to obtain the coupling agent.
Example 3
The embodiment provides a composite lysozyme sterilization and disinfection type ultrasonic coupling agent which comprises the following components in parts by weight:
2.5 parts of sodium alginate, 0.1 part of lysozyme, 0.5 part of poly aminopropyl biguanide, 0.1 part of benzalkonium chloride, 1.5 parts of trehalose, 2 parts of glycerol and 100 parts of water.
The compound lysozyme sterilization and disinfection type ultrasonic couplant is prepared according to the method of the embodiment 2.
Example 4
The embodiment provides a composite lysozyme sterilization and disinfection type ultrasonic coupling agent which comprises the following components in parts by weight:
3 parts of sodium alginate, 0.15 part of lysozyme, 1 part of polyaminopropyl biguanide, 0.2 part of benzalkonium chloride, 2 parts of trehalose, 3 parts of glycerol and 100 parts of water.
The compound lysozyme sterilization and disinfection type ultrasonic couplant is prepared according to the method of the embodiment 2.
Example 5
The embodiment provides a composite lysozyme sterilization and disinfection type ultrasonic coupling agent which comprises the following components in parts by weight:
5 parts of sodium alginate, 0.2 part of lysozyme, 2 parts of polyaminopropyl biguanide, 4 parts of benzalkonium chloride, 5 parts of trehalose, 5 parts of glycerol and 100 parts of water.
The compound lysozyme sterilization and disinfection type ultrasonic couplant is prepared according to the method of the embodiment 2.
Example 6
This example is intended to carry out the experiments of the bacteriostatic effect and skin irritation on the compound lysozyme sterilization and disinfection type ultrasonic couplant of examples 3-5.
Experiment of bacteriostatic effect
Culturing Escherichia coli (ATCC25922), Staphylococcus aureus (ATCC25923) and Candida albicans (ATCC10231) in sterilized beef broth liquid culture medium and Sabouraud's liquid culture medium at 37 deg.C for 24 hr under shaking. The method comprises the steps of vertically placing an oxford cup on the surface of a bacteria-containing culture medium by adopting an oxford cup method, adding 1ml of samples of the examples 3, 4 and 5 into the oxford cup respectively, using sterile water as a blank control, culturing for 24 hours, and observing and measuring the size of a bacteriostatic circle.
TABLE 1
Note: -: no bacteriostatic zone exists; +: the diameter of the bacteriostatic circle is less than 6 mm; ++: 6mm < diameter of bacteriostatic circle <8 mm; +++: the diameter of the inhibition zone is more than 8 mm.
Plate counting method for determining bacteriostasis rate
Lml examples 3, 4, 5 were mixed with 1ml of bacterial suspension, respectively. The counting was carried out by plate counting method in "determination of total number of colonies for food hygiene microorganism test".
TABLE 2
Note: the bacteriostasis rate is more than 99.0 percent and is marked as more than 99.0 percent; the bacteriostasis rate is below 1.00 percent and is recorded as <1.00 percent.
The data show that the invention has obvious effect of inhibiting various bacteria and can play a wider spectrum of antibacterial effect.
Skin irritation test
The compound lysozyme sterilization and disinfection type ultrasonic couplant of the embodiment 3-5 is respectively smeared on the skin of the rabbit, and no abnormality is found; no abnormality is observed after 24 h; no abnormality was observed after 48 hours. The compound lysozyme sterilization and disinfection type ultrasonic couplant in the examples 3-5 is not irritant to the skin of the rabbits.
The foregoing examples are merely illustrative of preferred embodiments of the present invention, and the scope of the present invention is not limited thereto, and the appended claims are intended to claim as broad a scope as can be conceived and the embodiments presented herein are merely illustrative of selected embodiments in accordance with all possible combinations of embodiments. Accordingly, it is applicants' intention that the appended claims are not to be limited by the choice of examples illustrating features of the invention. The technical solution and the inventive concept thereof according to the present invention should be equally replaced or changed within the protection scope of the present invention.
Claims (3)
1. The composite lysozyme sterilization and disinfection type ultrasonic coupling agent is characterized by comprising the following components in parts by weight:
0.1-0.5 part of lysozyme, 0.5-1 part of poly aminopropyl biguanide, 0.1-0.5 part of benzalkonium chloride, 1-6 parts of sodium alginate, 1-5 parts of trehalose, 2-5 parts of glycerol and 100 parts of water.
2. The ultrasonic couplant of claim 1, wherein the water is one of deionized water or distilled water.
3. The preparation method of the composite lysozyme sterilization and disinfection type ultrasonic couplant as claimed in claims 1-2, which is characterized by comprising the following steps:
s1: directly preparing, namely adding 0.1-0.5 part of lysozyme into 50-100 parts of purified water, stirring and dissolving, and then adding 0.5-1 part of poly (aminopropyl biguanide) and 0.1-0.5 part of benzalkonium chloride to prepare solution A;
s2: taking 50-100 parts of water, adding 1-5 parts of trehalose, dissolving, adding 1-6 parts of sodium alginate, heating and stirring until the mixture becomes gelatinous to prepare solution B;
s3: and adding the solution B into the solution A obtained in the step S1, uniformly stirring, and adding 2-5 parts of glycerol.
S4: stirring and defoaming in vacuum to obtain the coupling agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111481039.6A CN114028589A (en) | 2021-12-06 | 2021-12-06 | Composite lysozyme sterilization and disinfection type ultrasonic coupling agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111481039.6A CN114028589A (en) | 2021-12-06 | 2021-12-06 | Composite lysozyme sterilization and disinfection type ultrasonic coupling agent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114028589A true CN114028589A (en) | 2022-02-11 |
Family
ID=80146314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111481039.6A Pending CN114028589A (en) | 2021-12-06 | 2021-12-06 | Composite lysozyme sterilization and disinfection type ultrasonic coupling agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114028589A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117427188A (en) * | 2023-12-07 | 2024-01-23 | 山东源科生物科技股份有限公司 | Non-irritating antibacterial ultrasonic coupling agent |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249268A (en) * | 2008-03-20 | 2008-08-27 | 中山一枝生物技术有限公司 | Disinfection sterilizing type medical supersonic couplant and method of preparing the same |
| CN106581654A (en) * | 2016-12-27 | 2017-04-26 | 青岛琛蓝海洋生物工程有限公司 | Composite skin wound disinfectant and preparation method thereof |
| CN109568215A (en) * | 2019-01-22 | 2019-04-05 | 浙江维珍生物科技有限公司 | A kind of moist moisturizing maintenance essence cream and preparation method thereof containing dissolubility beeswax |
-
2021
- 2021-12-06 CN CN202111481039.6A patent/CN114028589A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249268A (en) * | 2008-03-20 | 2008-08-27 | 中山一枝生物技术有限公司 | Disinfection sterilizing type medical supersonic couplant and method of preparing the same |
| CN106581654A (en) * | 2016-12-27 | 2017-04-26 | 青岛琛蓝海洋生物工程有限公司 | Composite skin wound disinfectant and preparation method thereof |
| CN109568215A (en) * | 2019-01-22 | 2019-04-05 | 浙江维珍生物科技有限公司 | A kind of moist moisturizing maintenance essence cream and preparation method thereof containing dissolubility beeswax |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117427188A (en) * | 2023-12-07 | 2024-01-23 | 山东源科生物科技股份有限公司 | Non-irritating antibacterial ultrasonic coupling agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101111453B1 (en) | Antiseptic compositions, methods and systems | |
| CN104274490B (en) | Bactericidal composition including source of silver ions and menthol and application thereof | |
| CN101249268B (en) | Disinfection sterilizing type medical supersonic couplant and method of preparing the same | |
| CN104083398B (en) | A kind of medical protection flushing liquor and preparation method thereof | |
| CN108434954A (en) | It is a kind of multi-functional except formaldehyde deodorization eliminating smell agent | |
| RU2204394C2 (en) | Agent for treatment of fungal infection, gastric and duodenal ulcers induced by helicobacter pylori | |
| CN103997886A (en) | Method of treating a mammalian teat and related compositions | |
| CA2468419C (en) | Disinfectant solutions consisting essentially of a tetrasodium edta salt and a solvent and use thereof for disinfection | |
| CN101590287B (en) | Wound filling | |
| CN114028589A (en) | Composite lysozyme sterilization and disinfection type ultrasonic coupling agent and preparation method thereof | |
| CN108042578A (en) | A kind of health care vaginal jellies containing compound probiotic ingredient | |
| CN101543658B (en) | Cervical cap for preventing and treating cervical erosion and preparation method thereof | |
| CN104784103B (en) | Based on oligomeric amino acid amphiphile, amphiphilic molecule injectable anti-bacterial hydrogel | |
| CN104857550A (en) | Epsilon-polylysine-p-hydroxybenzene propanoic acid antibiotic hydrogel dressing and preparation method thereof | |
| CN102405935B (en) | Protamine compounded preparation, preparation method and application thereof | |
| CN107412213B (en) | Multifunctional external antibacterial and sterilizing agent and preparation method thereof | |
| CN113016798A (en) | Low-temperature bactericide | |
| CN111991417A (en) | Hypochlorous acid gel with physiological responsiveness and application thereof in skin wound surface | |
| EP0255875B1 (en) | Glutaraldehyde-based sterilising composition of antibacterial and antimycotic activity in an aqueous vehicle | |
| CN107638573B (en) | Antibacterial medical ultrasonic coupling agent and preparation method thereof | |
| CN113975188A (en) | Lysozyme skin disinfectant with skin protection function and preparation method thereof | |
| CN113632803B (en) | Quaternary ammonium salt complex iodine disinfectant and preparation method thereof | |
| CN106860891A (en) | A kind of benzalkonium bromide sodium choride irrigation and preparation method thereof | |
| JP2006201247A (en) | Sterilizing storage solution for contact lens | |
| CN107801732B (en) | Gas humidifying liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220211 |